Trial reportNeurogastroenterology and motility2008
Sensory signalling effects of tegaserod in patients with irritable bowel syndrome with constipation.
Trial report in Neurogastroenterology and motility, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Review
- Amino Acid Trp: The Far Out Impacts of Host and Commensal Tryptophan Metabolism.Frontiers in immunology · 2021Review
- The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System.Neural plasticity · 2019Review
- Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.Handbook of experimental pharmacology · 2017Review
- Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis.Journal of neurogastroenterology and motility · 2016Article
- Early investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.Expert opinion on investigational drugs · 2015Review
- The 5HT4 receptor agonist prucalopride suppresses abdominal nociception.Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections · 2015Article
- Recent advances in pharmacological treatment of irritable bowel syndrome.World journal of gastroenterology · 2014Review
- Visceral analgesic effect of 5-HT(4) receptor agonist in rats involves the rostroventral medulla (RVM).Neuropharmacology · 2014Article
- Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.Nature reviews. Gastroenterology & hepatology · 2013Review
- Effect of the 5-HT4 receptor and serotonin transporter on visceral hypersensitivity in rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- Serotonin and the GI tract.Current gastroenterology reports · 2009Article
- Visceral analgesics: drugs with a great potential in functional disorders?Current opinion in pharmacology · 2008Review
- Relationship between rectal sensitivity, symptoms intensity and quality of life in patients with irritable bowel syndrome.Alimentary pharmacology & therapeutics · 2008Article
- Novel techniques to study visceral hypersensitivity in irritable bowel syndrome.Current gastroenterology reports · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tegaserod relieves overall and multiple individual constipation-predominant irritable bowel syndrome (IBS-C) symptoms. However, mechanisms for the relief of abdominal pain/discomfort are not well understood. The effects of tegaserod on rectal sensitivity to distension were measured by the nociceptive flexion RIII reflex, as evidenced by spinal hyperexcitability (i.e. increase or facilitation of the RIII reflex), in IBS-C patients. A randomized, double-blind, placebo-controlled, parallel study was performed in 30 women with IBS-C. The effects of slow ramp rectal distension on the RIII reflex, recorded from the lower limb, were measured before [first experimental day (D1)] and after 7 days [day 8 (D8)] of placebo (n=15) or 6 mg tegaserod bid (n=15). Pressure-volume and sensation-volume relationships were measured during distension, and patients reported their IBS symptoms daily. On D1, rectal distension facilitated the RIII reflex in both treatment groups. On D8 vs D1 these facilitatory effects were significantly lower (P<0.001, analysis of variance) after tegaserod (mean reduction: -30.3+/-11.9%) than placebo (mean reduction: -10.1+/-12.9%). No significant changes in the volume-sensation relationship or differences in compliance were observed with tegaserod or placebo. In conclusion, tegaserod reduces the facilitatory effects of rectal distension on the RIII reflex in women with IBS-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.